Funder
Supported in part by a grant from Bristol-Myer Squibb
Publisher
Springer Science and Business Media LLC
Reference20 articles.
1. Boyle P (2012) Triple-negative breast cancer: epidemiological considerations and recommendations. Ann Oncol Supl 6:vi7–vi12
2. Lee FY, Smykla R, Johnston K, Menard K, McGlinchey K, Peterson RW et al (2009) Preclinical efficacy spectrum and pharmacokinetics of ixabepilone. Cancer Chemother Pharmocol 63:201–212
3. Lee FY, Borzilleri R, Fairchild CR, Kim SH, Long BH, Reventos-Suarez C et al (2001) BMS-247550: a novel epothilone analog with a mode of action similar to paclitaxel but possessing superior antitumor efficacy. Clin Cancer Res 7:1429–1437
4. Perez EA, Lerzo G, Pivot X, Thomas E, Vahdat L, Bossermann L et al (2007) Efficacy and safety of ixabepilone (BMS-247550) in a phase II study of patients with advanced breast cancer resistant to an anthracycline, a taxane, and capecitabine. J Clin Oncol 25:3407–3414
5. Thomas ES, Gomez HL, Li HL, Chung HC, Fein LE, Chan VF et al (2007) Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment. J Clin Oncol 25:5210–5217
Cited by
20 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献